New antibody drug takes aim at Hard-to-Treat lymphoma
NCT ID NCT04594642
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 28 times
Summary
This early-stage trial is testing a new drug called AZD0486 in people with B-cell non-Hodgkin lymphoma, a type of blood cancer. The drug is a bispecific antibody designed to help the body's immune cells find and kill cancer cells. About 226 participants who have already tried at least two other treatments will receive the drug to see if it is safe and to find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Tampa, Florida, 33612, United States
-
Research Site
Louisville, Kentucky, 40207, United States
-
Research Site
New Brunswick, New Jersey, 08901, United States
-
Research Site
Charlotte, North Carolina, 28204, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Pittsburgh, Pennsylvania, 15237, United States
-
Research Site
Austin, Texas, 78704, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Milwaukee, Wisconsin, 53226, United States
-
Research Site
Heidelberg, 3084, Australia
-
Research Site
Hobart, 7000, Australia
-
Research Site
Melbourne, 3004, Australia
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Kōtoku, 135-8550, Japan
-
Research Site
Nagoya, 460-0001, Japan
-
Research Site
Yamagata, 990-9585, Japan
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 06351, South Korea
-
Research Site
Seoul, 06591, South Korea
-
Research Site
Seoul, 120-752, South Korea
-
Research Site
Kaohsiung City, 833401, Taiwan
-
Research Site
Kweishan, 333, Taiwan
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 10002, Taiwan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD0486 (a bispecific antibody that helps immune cells attack lymphoma cells)
What this could lead to
If successful, this could lead to a new treatment option for people with B-cell non-Hodgkin lymphoma who have not responded to other therapies.
What could go wrong
This is an early phase 1 trial, so the main goal is safety, not proof of effectiveness. Side effects like cytokine release syndrome or nerve problems are possible, and the drug may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.